WO2008144253A1 - Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci - Google Patents

Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci Download PDF

Info

Publication number
WO2008144253A1
WO2008144253A1 PCT/US2008/063187 US2008063187W WO2008144253A1 WO 2008144253 A1 WO2008144253 A1 WO 2008144253A1 US 2008063187 W US2008063187 W US 2008063187W WO 2008144253 A1 WO2008144253 A1 WO 2008144253A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridine
carboxamide
methyl
pyrrolo
trifluoromethyl
Prior art date
Application number
PCT/US2008/063187
Other languages
English (en)
Inventor
Pingda Ren
Xia Wang
Songchun Jiang
Advait Nagle
Barun Okram
Yun He
Yongping Xie
Xing Wang
Shenlin Huang
Xiaodong Wang
Yi Liu
Pamela A. Albaugh
Nathanael S. Gray
Guobao Zhang
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of WO2008144253A1 publication Critical patent/WO2008144253A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the invention relates to protein kinase inhibitors, and methods of using such compounds.
  • the protein kinases represent a large family of proteins, which play a central role in the regulation of a wide variety of cellular processes and maintaining control over cellular function.
  • a partial, non-limiting, list of these kinases include: receptor tyrosine kinases such as platelet-derived growth factor receptor kinase (PDGFR), the nerve growth factor receptor, TrkB, Met, and the fibroblast growth factor receptor, FGFR-3 ; non-receptor tyrosine kinases such AbI and the fusion kinase Bcr-Abl, Lck, Csk, Fes, Bmx and Src; and serine/threonine kinases such as B-Raf, C-Raf, Sgk, MAP kinases (e.g., MKK4, MKK6, etc.) and SAPK2 ⁇ , SAPK2 ⁇ and SAPK3.
  • Aberrant kinase activity has been observed in many disease states including benign and malignant prolife
  • the invention provides compounds and pharmaceutical compositions thereof, which may be useful as protein kinase inhibitors.
  • the invention provides compounds having Formula (1): P A T E N T
  • X 1 and X 2 are independently CR or N; X 3 is CH or N, or C if attached to L 1 or R 4 ; Y is a 5-7 membered aryl or heteroaryl containing N, O or S; L 1 and L 2 are independently NRCO or CONR; R and R 1 are independently H or Ci_ 6 alkyl; R 2 is halo, or an optionally halogenated Ci_ 6 alkyl; R 3 is halo, an optionally halogenated Ci_ 6 alkyl, (CR 2 ) q R 8 or O(CR 2 ) q R 9 ; R 4 is H, halo, NR 6 R 7 , NR 5 (CR 2 ) P NR 6 R 7 , NR 5 CONR 6 R 7 or NR 5 CO 2 R 6 ; R 5 is H or Ci_6 alkyl;
  • R 6 and R 7 are independently H, an optionally halogenated Ci_ 6 alkyl, C 2 _ 6 alkenyl or C 2 _ 6 alkynyl; Ci_ 6 alkanol, (CR 2 ) q -R 8 or (CR 2 ) p O(CR 2 ) q R 9 ; or R 6 and R 7 together with N in NR 6 R 7 may form an optionally substituted ring;
  • R and R are independently an optionally substituted C 3 _ 7 cycloalkyl, 5-7 membered aryl, heterocyclic or heteroaryl; or R 9 is H; m is 1-4; and n, p and q are independently 0-4.
  • Y may be phenyl, thienyl, pyridyl, pyrazolyl or isoxazolyl.
  • R 2 is Ci_ 6 alkyl.
  • R 3 is halo, an optionally halogenated Ci_ 6 alkyl, (CR 2 ) q R 8 or O(CR 2 ) q R 9 ; and R 8 and R 9 are independently an optionally substituted piperidinyl, morpholinyl, imidazolyl or piperazinyl.
  • the invention provides compounds of Formula (2): P A T E N T
  • R 10 is halo, an optionally halogenated Ci_ 6 alkyl, or OCi_ 6 alkyl
  • R 11 is halo, Ci_ 6 alkyl, (CR 2 ) q R 8 or O(CR 2 ) q R 9 ;
  • R 8 and R 9 are independently an optionally substituted C 3 _ 7 cycloalkyl, 5-7 membered aryl, heterocyclic or heteroaryl; or R 9 is H; and k is 0-2.
  • R 10 may be CF 3 .
  • k is 0 or k is 1 and R 11 is halo, Ci_6 alkyl, (CR 2 ) q R 8 , O(CR 2 ) q R 9 ; and R 8 and R 9 are independently an optionally substituted piperidinyl, morpholinyl, imidazolyl or piperazinyl.
  • X 1 and X 2 may each be CH; or one of X 1 or X 2 is N, and the other is CH.
  • R 4 may be H, halo, NR 5 (CR 2 ) P NR 6 R 7 or NR 6 R 7 ;
  • R 6 and R 7 are independently H, Ci_ 6 alkyl, Ci_ 6 alkanol, or (CR 2 ) q R 8 ; or R 6 and R 7 together with N in NR 6 R 7 form an optionally substituted morpholinyl, piperidinyl or pyrrolidinyl; and
  • R 8 is an optionally substituted C 3 - 7 cycloalkyl, pyridyl, phenyl, morpholinyl, furanyl, naphthalenyl, piperazinyl, pyrimidinyl, imidazolyl, triazolyl, isothiazolyl, isoxazolyl, pyrazolyl or pyrazinyl.
  • a compound of Formula (1) is selected from: N-(3-(3-(trifluoromethyl)benzamido)phenyl)-lH-pyrrolo[2,3-b]pyridine-4-carboxamide, N-(3- (3-(trifluoromethyl)benzamido)phenyl)-lH-pyrrolo[2,3-b]pyridine-4-carboxamide, N-(2-methyl- 5-(3-(trifluoromethyl)benzamido)phenyl)-lH-pyrrolo[2,3-b]pyridine-4-carboxamide, N-(2- methyl-5-(3-(4-methyl-lH-imidazol-l-yl)-5-(trifluoromethyl)benzamido)phenyl)-lH- pyrrolo[2,3-b]pyridine-4-carboxamide, N-(5-(4-((4-ethylpiperazin-l-yl)methyl)-3- (trifluoro)phenyl)
  • the present invention provides pharmaceutical compositions comprising a compound having Formula (1) or (2), and a pharmaceutically acceptable excipient.
  • the invention provides methods for inhibiting a kinase, comprising administering to a system or a subject in need thereof, a therapeutically effective amount of a compound of Formula (1) or Formula (3),
  • X 1 and X 2 are independently CR or N;
  • X 3 is CH or N, or C if attached to L 1 or R 4 ;
  • Y is a 5-7 membered aryl or heteroaryl containing N, O or S;
  • L 1 and L 2 are independently NRCO or CONR;
  • R and R 1 are independently H or C 1-6 alkyl
  • R 2 is halo, or an optionally halogenated Ci_ 6 alkyl
  • R 3 is halo, an optionally halogenated Ci_ 6 alkyl, (CR 2 ) q R 8 or O(CR 2 ) q R 9 ;
  • R 4 is H, halo, NR 6 R 7 , NR 5 (CR 2 ) P NR 6 R 7 , NR 5 CONR 6 R 7 or NR 5 CO 2 R 6 ;
  • R 5 is Ci_ 6 alkyl
  • R 6 and R 7 are independently H, an optionally halogenated C 1-6 alkyl, C 2 _6 alkenyl or C 2 _6 alkynyl; Ci_ 6 alkanol, (CR 2 ) q -R 8 or (CR 2 ) p O(CR 2 ) q R 9 ; or R 6 and R 7 together with N in NR 6 R 7 may form an optionally substituted ring;
  • R 8 and R 9 are independently an optionally substituted C 3 - 7 cycloalkyl, 5-7 membered aryl, heterocyclic or heteroaryl; or R 9 is H;
  • R 12 is halo, an optionally halogenated Ci_ 6 alkyl, OCi_ 6 alkyl, NR 6 R 7 , NR 5 (CR 2 ) P NR 6 R 7 , NR 5 CONR 6 R 7 or NR 5 CO 2 R 6 ; P A T E N T
  • P1267PC10 m and o are independently 1-4; and n, p and q are independently 0-4; thereby inhibiting said kinase.
  • the invention also provides methods for modulating a protein kinase, comprising administering to a system or a subject in need thereof, a therapeutically effective amount of a compound having Formula (1), (2) or (3), or pharmaceutically acceptable salts or pharmaceutical compositions thereof, thereby modulating said protein kinase.
  • Examples of protein kinases which may be modulated using the compounds of the invention include but are not limited to AIk, AbI, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, BIk, Bmx, BTK, c-Kit, c-RAF, c-SRC, EphBl, EphB2, EphB4, FLTl, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFR ⁇ , PDGFR ⁇ , PKC ⁇ , p38 (p38 MAP kinase, SAPK2 ⁇ ), Src, SIK, Syk, Tie2 and TrkB kinases. More particularly, the compounds of Formula (1), (2) or (3) may be used for inhibiting B-Raf, Bcr-Abl or Lck or a combination thereof.
  • the invention provides methods for ameliorating a condition mediated by a protein kinase, such as a B-Raf, Bcr-Abl or Lck-mediated condition, comprising administering to a system or subject in need of such treatment an effective amount of a compound having Formula (1), (2) or (3) or pharmaceutically acceptable salts or pharmaceutical compositions thereof, and optionally in combination with a second therapeutic agent, thereby treating said condition.
  • a protein kinase such as a B-Raf, Bcr-Abl or Lck-mediated condition
  • the compounds of the invention may be used to treat a cell proliferative disorder, including but not limited to, melanoma, leukemia, chronic myelogenous leukemia, lymphoma, osteosarcoma, or a tumor of breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, neuronal, lung, uterine or gastrointestinal tumor.
  • a cell proliferative disorder including but not limited to, melanoma, leukemia, chronic myelogenous leukemia, lymphoma, osteosarcoma, or a tumor of breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, neuronal, lung, uterine or gastrointestinal tumor.
  • the compounds of the invention may also be used to treat an autoimmune disorder, including but not limited to systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, or multiple scleriosis.
  • a compound having Formula (1), (2) or (3) may be administered to a system comprising cells or tissues.
  • a compound having Formula (1), (2) or (3) may be administered to a human or animal subject.
  • the invention also provides for the use of a compound of Formula (1), (2) or (3), or pharmaceutically acceptable salts or pharmaceutical compositions thereof, for treating a condition mediated by a protein kinase.
  • the invention also provides for the use of a compound of Formula (1), (2) or (3), or pharmaceutically acceptable salts or pharmaceutical compositions thereof, in the manufacture of a medicament for treating a condition mediated by a protein kinase.
  • the protein kinases include, but are not limited to, AIk, AbI, Aurora- A, B-Raf, C-Raf, Bcr-Abl, BRK, BIk, Bmx, BTK, c-Kit, c-RAF, c-SRC, EphBl, EphB2, EphB4, FLTl, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFR ⁇ , PDGFR ⁇ , PKC ⁇ , p38 (p38 MAP kinase, SAPK2 ⁇ ), Src, SIK, Syk, Tie2 and TrkB kinases. More particularly, the protein kinasesare B-Raf, Bcr-Abl or Lck or a combination thereof.
  • the condition is a cell proliferative disorder or an autoimmune disorder.
  • the cell proliferative disorder include, but are not limited to, melanoma, leukemia, chronic myelogenous leukemia, lymphoma, osteosarcoma, or a tumor of breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, neuronal, lung, uterine or gastrointestinal tumor.
  • the autoimmune disorder include, but are not limited to, systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, or multiple sclerosis.
  • Alkyl refers to a moiety and as a structural element of other groups, for example halo-substituted-alkyl and alkoxy, and may be straight-chained or branched.
  • An optionally substituted alkyl, alkenyl or alkynyl as used herein may be optionally halogenated (e.g., CF 3 ), or may have one or more carbons that is substituted or replaced with a heteroatom, such as NR, O or S (e.g., -OCH 2 CH 2 O-, alkylthiol, thioalkoxy, alkylamine, etc).
  • Aryl refers to a monocyclic or fused bicyclic aromatic ring containing carbon atoms.
  • aryl may be phenyl or naphthyl.
  • Arylene means a divalent radical derived from an aryl group.
  • Heteroaryl as used herein is as defined for aryl above, where one or more of the ring members are a heteroatom.
  • heteroaryls include but are not limited to pyridyl, P A T E N T
  • Examples of carbocyclic rings include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylene, cyclohexanone, etc.
  • a "heterocyclic ring” as used herein is as defined for a carbocyclic ring above, wherein one or more ring carbons is a heteroatom.
  • heterocyclic rings include but are not limited to morpholino, pyrrolidinyl, pyrrolidin-2-one, piperazinyl, piperidinyl, piperidinone, l,4-dioxa-8-aza-spiro[4.5]dec-8-yl, etc.
  • co- administration or “combined administration” or the like as used herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
  • the term "pharmaceutical combination” as used herein refers to a product obtained from mixing or combining active ingredients, and includes both fixed and non-fixed combinations of the active ingredients.
  • the term "fixed combination” means that the active ingredients, e.g. a compound of Formula (1) and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
  • the term “non-fixed combination” means that the active ingredients, e.g. a compound of Formula (1) and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the active ingredients in the body of the patient.
  • cocktail therapy e.g. the administration of three or more active ingredients.
  • terapéuticaally effective amount means the amount of the subject compound that will elicit a biological or medical response in a cell, tissue, organ, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • administering means providing a compound of the invention and prodrugs thereof to a subject in need of treatment.
  • Kinase Panel is a list of kinases including but not limited to AbI, Abl(T315I), JAK2, JAK3, ALK, JNKl ⁇ l, ALK4, KDR, Aurora-A, Lck, BIk, MAPKl, Bmx, MAPKAP-K2, BRK, MEKl, CaMKII, Met, CDKl/cyclinB, p70S6K, CHK2, PAK2, CKl, PDGFR ⁇ , CK2, PDKl, c- Kit, Pim-2, C-Raf, PKA, CSK, PKB ⁇ , Src, PKC ⁇ , DYRK2, Plk3, EGFR, ROCK-I, Fes, Ron, FGFR-3, Ros, Flt3, SAPK2 ⁇ , Fms, SGK, Fyn, SIK, GSK3 ⁇ , Syk, IGFR, Tie-2, IKK ⁇ , TrkB, IR, WNK3, IRAK
  • the present invention provides compounds and pharmaceutical compositions thereof, which may be useful as protein kinase inhibitors.
  • the invention provides compounds having Formula (1):
  • X 1 and X 2 are independently CR or N;
  • X 3 is CH or N, or C if attached to L 1 or R 4 ;
  • Y is a 5-7 membered aryl or heteroaryl containing N, O or S;
  • L 1 and L 2 are independently NRCO or CONR;
  • R and R 1 are independently H or Ci_ 6 alkyl
  • R 2 is halo, or an optionally halogenated C 1-6 alkyl
  • R 3 is halo, an optionally halogenated Ci_ 6 alkyl, (CR 2 ) q R 8 or O(CR 2 ) q R 9 ;
  • R 4 is H, halo, NR 6 R 7 , NR 5 (CR 2 ) P NR 6 R 7 , NR 5 CONR 6 R 7 or NR 5 CO 2 R 6 ; P A T E N T
  • R 5 is d_ 6 alkyl
  • R 6 and R 7 are independently H, an optionally halogenated Ci_ 6 alkyl, C 2 - 6 alkenyl or C 2 - 6 alkynyl; Ci_ 6 alkanol, (CR 2 ) q -R 8 or (CR 2 ) p 0(CR 2 ) q R 9 ; or R 6 and R 7 together with N in NR 6 R 7 may form an optionally substituted ring;
  • R 8 and R 9 are independently an optionally substituted C 3 - 7 cycloalkyl, 5-7 membered aryl, heterocyclic or heteroaryl; or R 9 is H; m is 1-4; and n, p and q are independently 0-4.
  • the invention provides compounds of Formula (2):
  • R 10 is halo, an optionally halogenated Ci_ 6 alkyl, or OCi_ 6 alkyl
  • R 11 is halo, Ci_ 6 alkyl, (CR 2 ) q R 8 or O(CR 2 ) q R 9 ;
  • R 8 and R 9 are independently an optionally substituted C 3 - 7 cycloalkyl, 5-7 membered aryl, heterocyclic or heteroaryl; or R 9 is H; and k is 0-2.
  • the invention provides methods for inhibiting a kinase, comprising administering to a system or a subject in need thereof, a therapeutically effective amount of a compound of Formula (1) or Formula (3),
  • X 1 and X 2 are independently CR or N;
  • X 3 is CH or N, or C if attached to L 1 or R 4 ;
  • Y is a 5-7 membered aryl or heteroaryl containing N, O or S;
  • L 1 and L 2 are independently NRCO or CONR;
  • R and R 1 are independently H or C 1-6 alkyl
  • R 2 is halo, or an optionally halogenated C]_ 6 alkyl
  • R 3 is halo, an optionally halogenated C 1-6 alkyl, (CR 2 ) q R 8 or O(CR 2 ) q R 9 ;
  • R 4 is H, halo, NR 6 R 7 , NR 5 (CR 2 ) P NR 6 R 7 , NR 5 CONR 6 R 7 or NR 5 CO 2 R 6 ;
  • R 5 is Ci_ 6 alkyl
  • R 6 and R 7 are independently H, an optionally halogenated C 1-6 alkyl, C 2 _6 alkenyl or C 2 _6 alkynyl; Ci_ 6 alkanol, (CR 2 ) q -R 8 or (CR 2 ) p O(CR 2 ) q R 9 ; or R 6 and R 7 together with N in NR 6 R 7 may form an optionally substituted ring;
  • R 8 and R 9 are independently an optionally substituted C 3 - 7 cycloalkyl, 5-7 membered aryl, heterocyclic or heteroaryl; or R 9 is H;
  • R 12 is halo, an optionally halogenated Ci_ 6 alkyl, OCi_ 6 alkyl, NR 6 R 7 , NR 5 (CR 2 ) P NR 6 R 7 , NR 5 CONR 6 R 7 or NR 5 CO 2 R 6 ; m and 0 are independently 1-4; and n, p and q are independently 0-4; thereby inhibiting said kinase.
  • the present invention also includes all suitable isotopic variations of the compounds of the invention, or pharmaceutically acceptable salts thereof.
  • GNF Docket No.: P1267PC10 compound of the invention or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
  • isotopes that may be incorporated into the compounds of the invention and pharmaceutically acceptable salts thereof include but are not limited to isotopes of hydrogen, carbon, nitrogen and oxygen such as as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 17 O, 18 0, 35 S, 18 F, 36 Cl and 123 I.
  • isotopic variations of the compounds of the invention and pharmaceutically acceptable salts thereof are useful in drug and/or substrate tissue distribution studies.
  • 3 H and 14 C isotopes may be used for their ease of preparation and detectability.
  • substitution with isotopes such as 2 H may afford certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements.
  • Isotopic variations of the compounds of the invention or pharmaceutically acceptable salts thereof can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
  • Compounds having Formula (1), (2) and (3) may be useful as protein kinase inhibitors.
  • compounds having Formula (1), (2) or (3), and pharmaceutically acceptable salts, solvates, N-oxides, prodrugs and isomers thereof may be used for the treatment of a kinase-mediated condition or disease, such as diseases mediated by AIk, AbI, Aurora- A, B- Raf, C-Raf, Bcr-Abl, BRK, BIk, Bmx, BTK, c-Kit, c-RAF, c-SRC, EphBl, EphB2, EphB4, FLTl, Fms, Flt3, Fyn, JAK2, KDR, Lck, Lyn, PDGFR ⁇ , PDGFR ⁇ , PKC ⁇ , p38 (p38 MAP kinase, SAPK2 ⁇ ), Src, SIK, Syk, Tie2 and TrkB kinases, or a combination thereof.
  • the compounds of the invention may also be used in combination with a second therapeutic agent, for ameliorating a condition mediated by a protein kinase, such as a B-Raf, Bcr-Abl or Lck-mediated condition.
  • a protein kinase such as a B-Raf, Bcr-Abl or Lck-mediated condition.
  • the compounds of the invention may be used in combination with a chemotherapeutic agent to treat a cell proliferative disorder, including but not limited to, lymphoma, osteosarcoma, melanoma, or a tumor of breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, neuronal, lung, uterine or gastrointestinal tumor.
  • chemotherapeutic agents which may be used in the compositions and methods of the invention include but are not limited to anthracyclines, alkylating agents (e.g., mitomycin C), alkyl sulfonates, aziridines, ethylenimines, methylmelamines, nitrogen mustards, nitrosoureas, antibiotics, antimetabolites, folic acid analogs (e.g., dihydrofolate reductase inhibitors such as methotrexate), purine analogs, pyrimidine analogs, enzymes, podophyllotoxins, P A T E N T
  • chemotherapeutic agents which may be used in the compositions and methods of the invention include, but are not limited to, busulfan, improsulfan, piposulfan, benzodepa, carboquone, meturedepa, uredepa, altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylolomelamine, chlorambucil, chlornaphazine, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, dacarbazine,
  • Compounds of the invention are screened against the kinase panel (wild type and/or mutation thereof) and may modulate the activity of at least one panel kinase panel member. As such, compounds of the invention may be useful for treating diseases or disorders in which kinases contribute to the pathology and/or symptomology of the disease.
  • kinases that may be inhibited by the compounds and compositions described herein and against which the methods described herein may be useful include, but are not limited to AIk, AbI, Aurora-A, B- Raf, C-Raf, Bcr-Abl, BRK, BIk, Bmx, BTK, c-Kit, c-RAF, c-SRC, EphBl, EphB2, EphB4, P A T E N T
  • FLTl FLTl, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFR ⁇ , PDGFR ⁇ , PKC ⁇ , p38 (p38 MAP kinase, SAPK2 ⁇ ), Src, SIK, Syk, Tie2 and TrkB kinases, and mutant forms thereof.
  • the Ras-Raf- MEK-ERK signaling pathway mediates cellular response to growth signals. Ras is mutated to an oncogenic form in approximately 15% of human cancer.
  • the Raf family belongs to the serine/threonine protein kinase and it includes three members, A-Raf, B-Raf and C-Raf (or Raf-1).
  • the focus on Raf being a drug target has centered on the relationship of Raf as a downstream effector of Ras.
  • B-Raf may have a prominent role in the formation of certain tumors with no requirement for an activated Ras allele (Nature 417:949-954 (2002).
  • B-Raf mutations have been detected in a large percentage of malignant melanomas.
  • Existing medical treatments for melanoma are limited in their effectiveness, especially for late stage melanomas.
  • the compounds of the present invention also inhibit cellular processes involving B-Raf kinase, providing a new therapeutic opportunity for treatment of human cancers, such as melanoma.
  • Certain abnormal proliferative conditions are believed to be associated with Raf expression and are, therefore, believed to be responsive to inhibition of Raf expression. Abnormally high levels of expression of the Raf protein are also implicated in transformation and abnormal cell proliferation. These abnormal proliferative conditions are also believed to be responsive to inhibition of Raf expression. For example, expression of the c-Raf protein is believed to play a role in abnormal cell proliferation since it has been reported that 60% of all lung carcinoma cell lines express unusually high levels of c-Raf mRNA and protein.
  • abnormal proliferative conditions are hyper-proliferative disorders such as cancers, tumors, hyperplasia, pulmonary fibrosis, angiogenesis, psoriasis, atherosclerosis and smooth muscle cell proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
  • the cellular signaling pathway of which Raf is a part has also been implicated in inflammatory disorders characterized by T-cell proliferation (T-cell activation and growth), such as tissue graft rejection, endotoxin shock, and glomerular nephritis, for example.
  • the compounds of the present invention may also inhibit cellular processes involving c-Raf kinase.
  • c-Raf is activated by the Ras oncogene, which is mutated in a wide number of human cancers. Therefore inhibition of the kinase activity of c-Raf may provide a way to prevent Ras mediated tumor growth [Campbell, S. L., Oncogene, 17, 1395 (1998)].
  • the Src family of kinases is implicated in cancer, immune system dysfunction and bone remodeling diseases.
  • Members of the Src family include the following eight kinases in P A T E N T
  • Fyn encodes a membrane-associated tyrosine kinase that has been implicated in the control of cell growth.
  • Lck plays a role in T-cell signaling. Mice that lack the Lck gene have a poor ability to develop thymocytes. The function of Lck as a positive activator of T-cell signaling suggests that Lck inhibitors may be useful for treating autoimmune disease such as rheumatoid arthritis. Molina et al., Nature, 357, 161 (1992). Hck, Fgr and Lyn have been identified as important mediators of integrin signaling in myeloid leukocytes. Lowell et al., J. Leukoc. Diol., 65, 313 (1999). Inhibition of these kinase mediators may therefore be useful for treating inflammation. Boschelli et al., Drugs of the Future 2000, 25(7), 717.
  • Lyn a member of the Src family, plays a role in the regulation of B -cell immune responses. Lyn-deficient mice display disrupted B-cell function, leading to autoimmunity and defective mast cell degranulation. Studies have also suggested that Lyn is a negative regulator of apoptosis in various cell systems. In leukemic cells, Lyn is constitutively activated, and the inhibition of Lyn expression reversed proliferation. In addition, Lyn has been shown to be expressed in colon and PC cells, and that overexpression of a dominant active Lyn in colon cancer cell lines induced chemoresistance. (Goldenberg-Furmanov et al., Cancer Res. 64:1058-1066 (2004)).
  • c-Src transmits oncogenic signals of many receptors.
  • over- expression of EGFR or HER2/neu in tumors leads to the constitutive activation of c-Src, which is characteristic for the malignant cell but absent from the normal cell.
  • mice deficient in the expression of c-Src exhibit an osteopetrotic phenotype, indicating a key participation of c-Src in osteoclast function and a possible involvement in related disorders.
  • c-Src tyrosine kinase (CSK) influences the metastatic potential of cancer cells, particularly colon cancer.
  • c-Kit has a substantial homology to the PDGF receptor and to the CSF-I receptor (c- Fms). Investigations on various erythroid and myeloid cell lines indicate an expression of the c- Kit gene in early stages of differentiation (Andre et al., Oncogene 4 (1989), 1047-1049). Certain tumors such as glioblastoma cells likewise exhibit a pronounced expression of the c-Kit gene. P A T E N T
  • Eph receptors which include EphA and EphB subfamily, consist of the largest group of receptor tyrosine kinases. EphB was found to be overexpressed in several tumors including ovarian tumors, liver tumors, kidney tumors as well as melanomas. Downregulation of EphB signaling has shown to inhibit tumor growth and metastasis. Therefore, EphB may be an important target for anti-tumorigenic therapies. (Clevers et al., Cancer Res. 66:2-5 (2006); Heroult et al., Experimental Cell Res. 312: 642-650 (2006); and Batlle et al., Nature 435:1126- 1130 (2005)).
  • KDR Kinase insert domain-containing receptor
  • Fms-like tyrosine kinase referred to as "Fltl” hereinafter
  • Oncogene, 5: 519 (1990); Science, 255: 989 (1992)] belong to the receptor type tyrosine kinase family.
  • VEGF specifically binds to Fit- 1 and KDR at Kd values of 20 pM and 75 pM and that Fltl and KDR are expressed in vascular endothelial cells in a specific manner [Proc. Natl. Acad. Sci. USA, 90: 7533 (1993); Proc. Natl. Acad. Sci. USA, 90: 8915 (1993)].
  • FIt-I in various diseases, it has been reported that, in comparison with vascular endothelial cells in normal tissues, expression of FIt-I mRNA increases in tumor vascular endothelial cells of human glioblastoma tissues [Nature, 359: 845 (1992)] and tumor vascular endothelial cells of human digestive organ cancer tissues [Cancer Research, 53: 4727 (1993)]. Additionally, it has been reported that expression of FIt-I mRNA is observed by in situ hybridization in vascular endothelial cells of joints of patients with rheumatoid arthritis [J. Experimental Medicine, 180: 341 (1994)]. Studies also suggest that FIt-I plays an important role in tumor angiogenesis.
  • Flt3 is a member of the type III receptor tyrosine kinase (RTK) family.
  • Flt3 Flt3 (Fms-like tyrosine kinase) is also known as Flk-2 (fetal liver kinase T).
  • Flk-2 fetal liver kinase T.
  • Aberrant expression of the Flt3 gene has been documented in both adult and childhood leukemias including acute myeloid leukemia (AML), AML with trilineage myelodysplasia (AML/TMDS), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS).
  • AML acute myeloid leukemia
  • AML/TMDS AML with trilineage myelodysplasia
  • ALL acute lymphoblastic leukemia
  • MDS myelodysplastic syndrome
  • the leukemia cells express a constitutively active form of auto-phosphorylated (p) FLT3 tyrosine kinase on the cell surface.
  • the activity of p-FLT3 confers growth and survival advantage on the leukemic cells. Inhibition of p-FLT3 kinase activity induces apoptosis (programmed cell death) of the leukemic cells.
  • Abelson tyrosine kinase i.e. AbI, c-Abl
  • AbI AbI
  • c-Abl Abelson tyrosine kinase
  • the AbI protein appears to serve a complex role as a cellular module that integrates signals from various extracellular and intracellular sources and that influences decisions in regard to cell cycle and apoptosis.
  • Abelson tyrosine kinase includes sub-types derivatives such as the chimeric fusion (oncoprotein) Bcr-Abl with deregulated tyrosine kinase activity or the v-Abl.
  • Bcr-Abl is important in the pathogenesis of 95% of chronic myelogenous leukemia (CML) and 10% of acute lymphocytic leukemia.
  • Compounds of the present invention may inhibit AbI kinase, for example, v-Abl kinase.
  • the compounds of the present invention may also inhibit wild-type Bcr-Abl kinase and mutations of Bcr-Abl kinase, and thus may be suitable for the treatment of Bcr-Abl-positive cancer and tumor diseases, such as leukemias (e.g., chronic myeloid leukemia and acute lymphoblastic leukemia) and other proliferation disorders related to Bcr-Abl.
  • Bcr-Abl-positive cancer and tumor diseases such as leukemias (e.g., chronic myeloid leukemia and acute lymphoblastic leukemia) and other proliferation disorders related to Bcr-Abl.
  • Compounds of the present invention may also be effective against leukemic stem cells, and may be potentially useful for the purification of these cells in vitro after removal of said cells (for example, bone marrow removal), and reimplantation of the cells once they have been cleared of cancer cells (for example, reimplantation of purified bone marrow cells).
  • Anaplastic lymphoma kinase (ALK), a member of the insulin receptor superfamily of receptor tyrosine kinases, has been implicated in oncogenesis in hematopoietic and non- hematopoietic tumors.
  • ALK insulin receptor superfamily of receptor tyrosine kinases
  • the aberrant expression of full-length ALK receptor proteins has been reported in neuroblastomas and glioblastomas; and ALK fusion proteins have occurred in anaplastic large cell lymphoma.
  • the study of ALK fusion proteins has also raised the possibility of new therapeutic treatments for patients with ALK-positive malignancies. (Pulford et al., Cell. MoI. Life Sci. 61:2939-2953 (2004)).
  • Aurora-A a serine/threonine mitotic kinase
  • Aurora-A has been reported to be overexpressed in various human cancers, and its overexpression induces aneuploidy, centrosome amplification and tumorigenic transformation in cultured human and rodent cells.
  • Bmx/Etk non-receptor tyrosine protein kinase has been implicated in endothelial cell migration and tube formation in vitro.
  • Bmx in endothelium and bone marrow has also been reported to play an important role in arteriogenesis and angiogenesis in vivo, suggesting that Bmx P A T E N T
  • GNF Docket No.: P1267PC10 may be a novel target for the treatment of vascular diseases such as coronary artery disease and peripheral arterial disease. (He et al., J. Clin. Invest. 116:2344-2355 (2006)).
  • Bruton's tyrosine kinase (BTK) gene encodes a cytoplasmic tyrosine kinase that plays an essential role in mediating BCR signaling, (de Weers et al., J. Biol. Chem. 269:23857-23860 (1994); Kurosaki et al., Immunity. 12:1-5 (2000)).
  • Defects in the BTK gene cause Agammaglobulinemia, an X- linked immunodeficiency characterized by failure to produce mature B lymphocyte cells and associated with a failure of Ig heavy chain rearrangement.
  • Breast tumor kinase (Brk) is a soluble protein-tyrosine kinase overexpressed in the majority of breast cancers and also in normal skin and gut epithelium, but not in normal breast epithelial cells. (Zhang et al., J Biol. Chem. 280:1982-1991 (2005)).
  • the Janus kinases are a family of tyrosine kinases consisting of JAKl, JAK2, JAK3 and TYK2.
  • the JAKs play an important role in cytokine signaling.
  • the down-stream substrates of the JAK family of kinases include the signal transducer and activator of transcription (STAT) proteins.
  • STAT signal transducer and activator of transcription
  • JAK/STAT signaling has been implicated in the mediation of many abnormal immune responses such as allergies, asthma, autoimmune diseases such as transplant rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis, as well as in solid and hematologic malignancies such as leukemias and lymphomas.
  • VEGF vascular endothelium growth factor
  • VEC vascular endothelial cell
  • TC tumor cell
  • KDR KDR is the main receptor which gives play to VEGF functions. KDR is highly expressed on the TC and tumor VEC while lowly expressed on the normal tissues.
  • MAPKs Mitogen- activated protein kinases
  • MKKs mitogen- activated protein kinase kinases
  • cytokines including but not limited to TNF ⁇ , IL-6, IL-8 and IL-l ⁇ .
  • Peripheral blood monocytes PBMCs
  • LPS lipopoly saccharide
  • P38 inhibitors efficiently block this effect when PBMCs are pretreated with such compounds prior to stimulation with LPS.
  • P38 inhibitors are efficacious in animal models of inflammatory disease. The destructive effects of many disease states are caused by the over production of pro-inflammatory cytokines. The ability of p38 inhibitors to regulate this overproduction makes them useful as disease modifying agents.
  • Molecules that block p38's function have been shown to be effective in inhibiting bone resorption, inflammation, and other immune and inflammation-based pathologies.
  • a safe and effective p38 inhibitor would provide a means to treat debilitating diseases that can be regulated by modulation of p38 signaling like. Therefore, compounds of the invention that inhibit p38 activity are useful for the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, autoimmune diseases, and for the treatment of other cytokine mediated diseases.
  • PDGF Platinum-derived Growth Factor
  • PDGFR PDGF receptor
  • Compounds of the present invention may be used not only as a tumor-inhibiting substance, for example in small cell lung cancer, but also as an agent to treat non-malignant proliferative disorders, such as atherosclerosis, thrombosis, psoriasis, scleroderma and fibrosis.
  • non-malignant proliferative disorders such as atherosclerosis, thrombosis, psoriasis, scleroderma and fibrosis.
  • Compounds of the present invention may also be useful for the protection of stem cells, for example to combat the hemotoxic effect of chemotherapeutic agents, such as 5-fluoruracil, and in asthma.
  • Compounds of the invention may especially be used for the treatment of diseases, which respond to an inhibition of the PDGF receptor kinase.
  • Compounds of the present invention may exhibit useful effects in the treatment of disorders arising as a result of transplantation, for example, allogenic transplantation, especially tissue rejection, such as obliterative bronchiolitis (OB), i.e. a chronic rejection of allogenic lung transplants.
  • OB obliterative bronchiolitis
  • OB obliterative bronchiolitis
  • those with OB often show an elevated PDGF concentration in bronchoalveolar lavage fluids.
  • Compounds of the present invention may also be effective against diseases associated with vascular smooth-muscle cell migration and proliferation (where PDGF and PDGFR often also play a role), such as restenosis and atherosclerosis.
  • diseases associated with vascular smooth-muscle cell migration and proliferation where PDGF and PDGFR often also play a role
  • diseases associated with vascular smooth-muscle cell migration and proliferation such as restenosis and atherosclerosis.
  • PKC Protein kinase C
  • the stress activated protein kinases are a family of protein kinases that represent the penultimate step in signal transduction pathways that result in activation of the c-Jun transcription factor and expression of genes regulated by c-Jun.
  • c-Jun is involved in the transcription of genes that encode proteins involved in the repair of DNA that is damaged due to genotoxic insults. Therefore, agents that inhibit SAPK activity in a cell prevent DNA repair and sensitize the cell to agents that induce DNA damage or inhibit DNA synthesis and induce apoptosis of a cell or that inhibit cell proliferation.
  • SNFlLK locus also known as SIK
  • Snf Ilk is also expressed in skeletal muscle progenitor cells of the somite beginning at 9.5 dpc, suggesting a more general role for snf Ilk in the earliest stages of muscle growth and/or differentiation.
  • Syk is a tyrosine kinase that plays an important role in mast cell degranulation and eosinophil activation. Accordingly, Syk kinase is implicated in various allergic disorders, in particular asthma. It has been shown that Syk binds to the phosphorylated gamma chain of the Fc ⁇ Rl receptor via N-terminal SH 2 domains, and is important for downstream signaling.
  • TrkA, TrkB, TrkC The Trk family of neurotrophin receptors promotes the survival, growth and differentiation of the neuronal and non-neuronal tissues.
  • the TrkB protein is expressed in neuroendocrine-type cells in the small intestine and colon, in the alpha cells of the pancreas, in the monocytes and macrophages of the lymph nodes and of the spleen, and in the granular layers of the epidermis (Shibayama and Koizumi, 1996). Expression of the TrkB protein has been associated with an unfavorable progression of Wilms tumors and of neuroblastomas. Moreover, TrkB is expressed in cancerous prostate cells but not in normal cells.
  • the signaling pathway downstream of the Trk receptors involves the cascade of MAPK activation through the She, activated Ras, ERK-I and ERK-2 genes, and the PLC-gamma transduction pathway (Sugimoto et al., Jpn J. Cancer Res. 2001 Feb; 92(2): 152-60).
  • RTKs The class III receptor tyrosine kinases (RTKs), which include c-FMS, c-KIT, FLT3, platelet-derived growth factor receptor ⁇ (PDGFR ⁇ ) and / ⁇ PDGFR/)), have been reported to be associated with the pathogenesis of an increasing number of malignancies. (Blume-Jensen et al., Nature 411:355-565 (2001); Scheijin et al., Oncogene 21:3314-3333 (2002)).
  • the present invention further provides a method for preventing or treating any of the diseases or disorders described above in a subject in need of such treatment, which method comprises administering to said subject a therapeutically effective amount of a compound of Formula (1), (2) or (3) or a pharmaceutically acceptable salt thereof.
  • a therapeutically effective amount of a compound of Formula (1), (2) or (3) or a pharmaceutically acceptable salt thereof for any of the above uses, the required dosage will vary depending on the mode of administration, the particular condition to be treated and the effect desired. (See, "Administration and Pharmaceutical Compositions," infra) P A T E N T
  • compounds of the invention will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents.
  • a therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.03 to 2.5 mg/kg per body weight.
  • An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5 mg to about 100 mg, conveniently administered, e.g. in divided doses up to four times a day or in retard form.
  • Suitable unit dosage forms for oral administration comprise from ca. 1 to 50 mg active ingredient.
  • Compounds of the invention may be administered as pharmaceutical compositions by any conventional route, in particular enterally, e.g., orally in the form of tablets or capsules; parenterally, e.g., in the form of injectable solutions or suspensions; topically, e.g., in the form of lotions, gels, ointments or creams; or in a nasal or suppository form.
  • compositions comprising a compound of the present invention in free form or in a pharmaceutically acceptable salt form in association with at least one pharmaceutically acceptable carrier or diluent may be manufactured in a conventional manner by mixing, granulating or coating methods.
  • oral compositions can be tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; and/or b) lubricants, e.g., silica, talcum, stearic acid or its magnesium or calcium salt and/or polyethyleneglycol.
  • diluents e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine
  • lubricants e.g., silica, talcum, stearic acid or its magnesium or calcium salt and
  • Tablets may further comprise c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone; and if desired, d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners.
  • Injectable compositions can be aqueous isotonic solutions or suspensions, and suppositories can be prepared from fatty emulsions or suspensions.
  • compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
  • adjuvants such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers.
  • Suitable formulations for transdermal applications include an effective amount of a compound of the present invention with a carrier.
  • a carrier can include absorbable P A T E N T
  • transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
  • Matrix transdermal formulations may also be used.
  • Suitable formulations for topical application, e.g., to the skin and eyes, may be aqueous solutions, ointments, creams or gels well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
  • Compounds of the invention may be administered in therapeutically effective amounts in combination with one or more therapeutic agents (pharmaceutical combinations).
  • therapeutic agents for example, synergistic effects can occur with other immunomodulatory or anti-inflammatory substances, for example when used in combination with cyclosporin, rapamycin, or ascomycin, or immunosuppressant analogues thereof, for example cyclosporin A (CsA), cyclosporin G, FK-506, rapamycin, or comparable compounds, corticosteroids, cyclophosphamide, azathioprine, methotrexate, brequinar, leflunomide, mizoribine, mycophenolic acid, mycophenolate mofetil, 15-deoxyspergualin, immunosuppressant antibodies, especially monoclonal antibodies for leukocyte receptors, for example MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD45, CD58 or their ligands, or other immunomodulatory compounds, such as CT
  • the invention also provides for a pharmaceutical combinations, e.g. a kit, comprising a) a first agent which is a compound of the invention as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent.
  • a pharmaceutical combination e.g. a kit, comprising a) a first agent which is a compound of the invention as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent.
  • the kit can comprise instructions for its administration.
  • a compound of the invention may be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid.
  • a pharmaceutically acceptable base addition salt of a compound of the invention may be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base.
  • the salt forms of the compounds of the invention may be prepared using salts of the starting materials or intermediates.
  • the free acid or free base forms of the compounds of the invention may be prepared from the corresponding base addition salt or acid addition salt from, respectively.
  • a compound of the invention in an acid addition salt form may be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like).
  • a suitable base e.g., ammonium hydroxide solution, sodium hydroxide, and the like.
  • a compound of the invention in a base addition salt form may be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc.).
  • Compounds of the invention in unoxidized form may be prepared from N-oxides of compounds of the invention by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 8O 0 C.
  • a reducing agent e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like
  • a suitable inert organic solvent e.g. acetonitrile, ethanol, aqueous dioxane, or the like
  • Prodrug derivatives of the compounds of the invention may be prepared by methods known to those of ordinary skill in the art (See e.g., Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985).
  • appropriate prodrugs may be prepared by reacting a non-derivatized compound of the invention with a suitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbanochloridate, para-nitrophenyl carbonate, or the like).
  • Hydrates of compounds of the present invention may be conveniently prepared or formed during the process of the invention, as solvates (e.g., hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
  • Compounds of the invention may be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers.
  • Resolution of enantiomers may be carried out using covalent diastereomeric derivatives of the compounds of the invention, or by using dissociable complexes (e.g., crystalline diastereomeric salts).
  • Diastereomers have distinct physical properties (e.g., melting P A T E N T
  • the diastereomers may be separated by chromatography, or by separation/resolution techniques based upon differences in solubility.
  • the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
  • a more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981.
  • Table 1 describes representative compounds obtained by the above procedure.
  • Table 2 describes representative compounds obtained by the above procedure.
  • Table 3 describes representative compounds obtained by the above procedure.
  • the title compound is prepared from 4-methylamino-lH-pyrrolo[2,3-&]pyridine-5- carboxylic acid (5-amino-2-methyl-phenyl)-amide and 3-(4-ethyl-piperazin-l-yl)-5- trifluoromethyl-benzoic acid in a manner similar to that of Example 3 for 1H-Pyrrolo[2,3- &]pyridine-5-carboxylic acid [2-methyl-5-(4-morpholin-4-ylmethyl-3-trifluoromethyl- benzoylamino)-phenyl]-amide.
  • Table 6 describes representative compounds obtained by the above procedure.
  • Table 7 describes representative compounds obtained by the above procedure.
  • Table 8 describes representative compounds obtained by the above procedure.
  • Compounds of the present invention may be assayed to measure their capacity to inhibit a kinase panel, including but not limited to AIk, AbI, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, BIk, Bmx, BTK, c-Kit, c-RAF, c-SRC, EphBl, EphB2, EphB4, FLTl, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFR ⁇ , PDGFR ⁇ , PKC ⁇ , p38 (p38 MAP kinase, SAPK2 ⁇ ), Src, SIK, Syk, Tie2 and TrkB kinases.
  • Compounds of the invention may be tested for their ability to inhibit the activity of b- Raf.
  • the assay is carried out in 384-well MaxiSorp plates (NUNC) with black walls and clear bottom.
  • the substrate, I ⁇ B ⁇ is diluted in DPBS (1:750) and 15 ⁇ l is added to each well.
  • the plates are incubated at 4 0 C overnight and washed 3 times with TBST (25 mM Tris, pH 8.0, 150 P A T E N T
  • Phosph- I ⁇ B ⁇ (Ser32/36) antibody is diluted in Superblock (1:10,000) and 15 ⁇ l is added to each well. The plates are incubated at 4 0 C overnight and washed 6 times with TBST.
  • AP-conjugated goat- anti-mouse IgG is diluted in Superblock (1: 1,500) and 15 ⁇ l is added to each well. Plates are incubated at room temperature for 1 hour and washed 6 times with TBST. 15 ⁇ l of fluorescent Attophos AP substrate (Promega) is added to each well and plates are incubated at room temperature for 15 minutes. Plates are read on Acquest or Analyst GT using a Fluorescence Intensity Program (Excitation 455 nm, Emission 580 nm).
  • A375 cell line (ATCC) is derived from a human melanoma patient and has a V599E mutation on the B-Raf gene. The levels of phosphorylated MEK are elevated due to the mutation of B-Raf.
  • Sub-confluent to confluent A375 cells are incubated with compounds for 2 hours at 37 0 C in serum free medium. Cells are then washed once with cold PBS and lysed with the lysis buffer containing 1% Triton XlOO. After centrifugation, the supernatants are subjected to SDS-PAGE, and then transferred to nitrocellulose membranes.
  • the membranes are then subjected to western blotting with anti-phospho-MEK antibody (ser217/221) (Cell Signaling).
  • the amount of phosphorylated MEK is monitored by the density of phospho-MEK bands on the nitrocellulose membranes.
  • the murine cell line 32D hemopoietic progenitor cell line may be transformed with Bcr-Abl cDNA (32D-p210). These cells are maintained in RPMI/10% fetal calf serum (RPMI/FCS) supplemented with penicillin 50 ⁇ g/mL, streptomycin 50 ⁇ g/mL and L-glutamine 200 mM. Untransformed 32D cells are similarly maintained with the addition of 15% of WEHI conditioned medium as a source of IL3.
  • RPMI/10% fetal calf serum RPMI/FCS
  • Untransformed 32D cells are similarly maintained with the addition of 15% of WEHI conditioned medium as a source of IL3.
  • 50 ⁇ l of a 32D or 32D-p210 cells suspension are plated in Greiner 384 well microplates (black) at a density of 5000 cells per well.
  • 50 nl of test compound (1 mM in DMSO stock solution) is added to each well (STI571 is included as a positive control).
  • the cells are incubated for 72 hours at 37 °C, 5% CO 2 .
  • 10 ⁇ l of a 60% Alamar Blue solution (Tek diagnostics) is added to each well and the cells are incubated for an additional 24 hours.
  • the fluorescence intensity (Excitation at 530 nm, Emission at 580 nm) is quantified using the AcquestTM system (Molecular Devices).
  • 32D-p210 cells are plated into 96 well TC plates at a density of 15,000 cells per well. 50 ⁇ L of two fold serial dilutions of the test compound (C max is 40 ⁇ M) are added to each well (STI571 is included as a positive control). After incubating the cells for 48 hours at 37 °C, 5% CO 2 , 15 ⁇ L of MTT (Promega) is added to each well and the cells are incubated for an additional 5 hours. The optical density at 570 nm is quantified spectrophotometrically and IC 50 values, the concentration of compound required for 50% inhibition, determined from a dose response curve.
  • test compounds of the present invention may demonstrate an apoptotic effect on the 32D-p210 cells but not induce apoptosis in the 32D parental cells.
  • Bcr-Abl autophosphorylation is quantified with capture Elisa using a c-Abl specific capture antibody and an antiphosphotyrosine antibody.
  • 32D-p210 cells are plated in 96 well TC plates at 2xlO 5 cells per well in 50 ⁇ L of medium. 50 ⁇ L of two fold serial dilutions of test compounds (C max is 10 ⁇ M) are added to each well (STI571 is included as a positive control). The cells are incubated for 90 minutes at 37 °C, 5% CO 2 . The cells are then treated for 1 hour on P A T E N T
  • lysis buffer 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mM EGTA and 1% NP-40
  • 50 ⁇ L of cell lysate is added to 96 well optiplates previously coated with
  • test compounds of the invention may inhibit the proliferation of the Bcr-Abl expressing cells, inhibiting the cellular Bcr-Abl autophosphorylation in a dose-dependent manner.
  • Compounds of the invention may be tested for their antiproliferative effect on Ba/F3 cells expressing either wild type or the mutant forms of Bcr-Abl (G250E, E255V, T315I, F317L, M351T) that confers resistance or diminished sensitivity to STI571.
  • the antiproliferative effect of these compounds on the mutant-Bcr-Abl expressing cells and on the non transformed cells may be tested at 10, 3.3, 1.1 and 0.37 ⁇ M as described above (in media lacking IL3).
  • the IC 50 values of the compounds lacking toxicity on the untransformed cells are determined from the dose response curves obtained as described above.
  • Kinase activity assay with purified FGFR-3 (Upstate) is carried out in a final volume of 10 ⁇ L containing 0.25 ⁇ g/mL of enzyme in kinase buffer (30 mM Tris-HCl pH7.5, 15 mM MgCl 2 , 4.5 mM MnCl 2 , 15 ⁇ M Na 3 VO 4 and 50 ⁇ g/mL BSA), and substrates (5 ⁇ g/mL biotin- poly-EY(Glu, Tyr) (CIS-US, Inc.) and 3 ⁇ M ATP).
  • the first solution of 5 ⁇ l contains the FGFR-3 enzyme in kinase buffer was first dispensed into 384-well format ProxiPlate® (Perkin- Elmer) followed by adding 50 nL of compounds dissolved in DMSO, then 5 ⁇ l of second solution contains the substrate (poly-EY) and ATP in kinase buffer was added to each wells.
  • the reactions are incubated at room temperature for one hour, stopped by adding 10 ⁇ L of HTRF detection mixture, which contains 30 mM Tris-HCl pH 7.5, 0.5 M KF, 50 mM ETDA, 0.2 mg/mL BSA, 15 ⁇ g/mL streptavidin-XL665 (CIS-US, Inc.) and 150 ng/mL cryptate conjugated anti-phosphotyrosine antibody (CIS-US, Inc.). After one hour of room temperature P A T E N T
  • Compounds of the invention are tested for their ability to inhibit transformed Ba/F3- TEL-FGFR3 cells proliferation, which is dependent on FGFR-3 cellular kinase activity.
  • Ba/F3- TEL-FGFR3 are cultured up to 800,000 cells/mL in suspension, with RPMI 1640 supplemented with 10% fetal bovine serum as the culture medium. Cells are dispensed into 384-well format plate at 5000 cell/well in 50 ⁇ L culture medium.
  • Compounds of the invention are dissolved and diluted in dimethylsulfoxide (DMSO). Twelve points 1:3 serial dilutions are made into DMSO to create concentrations gradient ranging typically from 10 mM to 0.05 ⁇ M.
  • DMSO dimethylsulfoxide
  • AlamarBlue® (TREK Diagnostic Systems), which can be used to monitor the reducing environment created by proliferating cells, are added to cells at a final concentration of 10%. After additional four hours of incubation in a 37 0 C cell culture incubator, fluorescence signals from reduced AlamarBlue® (Excitation at 530 nm, Emission at 580 nm) are quantified on Analyst GT (Molecular Devices Corp.). IC 50 values are calculated by linear regression analysis of the percentage inhibition of each compound at 12 concentrations.
  • Compounds of the invention may be tested for their ability to inhibit transformed Ba/F3-FLT3-ITD or Ba/F3-Tel-PDGFR ⁇ cells proliferation, which is dependent on FLT3 or PDGFR ⁇ cellular kinase activity.
  • Ba/F3-FLT3-ITD or Ba/F3-Tel-PDGFR ⁇ are cultured up to 800,000 cells/mL in suspension, with RPMI 1640 supplemented with 10% fetal bovine serum as the culture medium. Cells are dispensed into 384-well format plate at 5000 cell/well in 50 ⁇ L culture medium.
  • Compounds of the invention are dissolved and diluted in dimethylsulfoxide (DMSO). Twelve points 1:3 serial dilutions are made into DMSO to create concentrations gradient ranging typically from 10 mM to 0.05 ⁇ M. Cells are added with 50 nL of diluted P A T E N T
  • AlamarBlue® (TREK Diagnostic Systems), which can be used to monitor the reducing environment created by proliferating cells, are added to cells at final concentration of 10%.
  • fluorescence signals from reduced AlamarBlue® (Excitation at 530 nm, Emission at 580 nm) are quantified on Analyst GT (Molecular Devices Corp.).
  • IC 50 values are calculated by linear regression analysis of the percentage inhibition of each compound at 12 concentrations.
  • Compounds of the invention may be assessed for their ability to inhibit individual members of a panel of kinases (a partial, non- limiting list of kinases includes: AIk, AbI, Aurora- A, B-Raf, Bcr-Abl, BRK, BIk, Bmx, c-Kit, c-Raf, cSRC, CSK, EphB, FLTl, Fms, Fyn, JAK2, KDR, Lck, Lyn, PDGFR ⁇ , PDGFR ⁇ , PKC ⁇ , p38 (p38 MAP kinase, SAPK2 ⁇ ), SIK, Src, Syk, Tie2 and TrkB kinases).
  • a partial, non- limiting list of kinases includes: AIk, AbI, Aurora- A, B-Raf, Bcr-Abl, BRK, BIk, Bmx, c-Kit, c-Raf, cSRC, CSK,
  • the compounds are tested in duplicates at a final concentration of 10 ⁇ M following this generic protocol, using varying kinase buffer composition and substrates for the different kinases included in the "Upstate KinaseProfilerTM panel.
  • Kinase buffer 2.5 ⁇ L, 10x - containing MnCl 2 when required
  • active kinase 0.001-0.01 Units; 2.5 ⁇ L
  • specific or Poly(Glu4-Tyr) peptide 5-500 ⁇ M or .01 mg/ml
  • kinase buffer and kinase buffer 50 ⁇ M; 5 ⁇ L
  • kinase buffer 50 ⁇ M; 5 ⁇ L
  • the reaction mixture is spotted (20 ⁇ L) onto a 2cm x 2cm P81 (phosphocellulose, for positively charged peptide substrates) or Whatman No. 1 (for Poly (Glu4-Tyr) peptide substrate) paper square.
  • the assay squares are washed 4 times, for 5 minutes each, with 0.75% phosphoric acid and washed once with acetone for 5 minutes.
  • the assay squares are transferred to a scintillation vial, 5 ml scintillation cocktail are added and 32 P P A T E N T
  • Compounds of Formula (1), (2) or (3) in free form or in pharmaceutically acceptable salt form may exhibit valuable pharmacological properties, for example, as indicated by the in vitro tests described in this application.
  • the IC 50 value in those experiments is given as that concentration of the test compound in question that results in a cell count that is 50 % lower than that obtained using the control without inhibitor.
  • compounds of the invention have IC 50 values from 1 nM to 10 ⁇ M against one or more of the following kinases: AIk, AbI, Aurora- A, B-Raf, C-Raf, Bcr-Abl, BRK, BIk, Bmx, BTK, c-Kit, c-RAF, c-SRC, EphBl, EphB2, EphB4, FLTl, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFR ⁇ , PDGFR ⁇ , PKC ⁇ , p38 (p38 MAP kinase, SAPK2 ⁇ ), Src, SIK, Syk, Tie2 and TrkB kinases.
  • compounds of the invention have IC 50 values from 0.01 ⁇ M to 5 ⁇ M. In other examples, compounds of the invention have IC 50 values from 0.01 ⁇ M to 1 ⁇ M, or more particularly from 1 nM to 1 ⁇ M. In yet other examples, compounds of the invention have IC 50 values of less than 1 nM or more than 10 ⁇ M.
  • Compounds of Formula (1), (2) or (3) may exhibit a percentage inhibition of greater than 50%, or in other embodiments, may exhibit a percentage inhibition greater than about 70%, against one or more of the following kinases at 10 ⁇ M: AIk, AbI, Aurora-A, B-Raf, C-Raf, Bcr- Abl, BRK, BIk, Bmx, BTK, c-Kit, c-RAF, c-SRC, EphBl, EphB2, EphB4, FLTl, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFR ⁇ , PDGFR ⁇ , PKC ⁇ , p38 (p38 MAP kinase, SAPK2 ⁇ ), Src, SIK, Syk, Tie2 and TrkB kinases.
  • AIk AbI, Aurora-A, B-Raf, C-Raf, Bcr- Abl, BRK, BIk, B

Abstract

L'invention concerne des composés représentés par la formule (l) et des compositions pharmaceutiques de ceux-ci qui sont utiles en tant qu'inhibiteurs de la protéine kinase, et des procédés destinés à utiliser de tels composés pour traiter, améliorer ou prévenir un état pathologique associé à une activité kinase anormale ou dérégulée. Dans certains modes de réalisation, l'invention propose des procédés destinés à utiliser de tels composés afin de traiter, d'améliorer ou de prévenir des maladies ou des troubles qui impliquent une activation anormale des kinases AIk, AbI, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, BIk, Bmx, BTK, c-Kit, c-RAF, CSK, c-SRC, EphBl, EphB2, EphB4, FLTl, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFRalpha, PDGFRbeta, PKCalpha, SAPK2alpha, Src, SIK, Syk, Tie2 et TrkB.
PCT/US2008/063187 2007-05-14 2008-05-09 Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci WO2008144253A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91775807P 2007-05-14 2007-05-14
US60/917,758 2007-05-14

Publications (1)

Publication Number Publication Date
WO2008144253A1 true WO2008144253A1 (fr) 2008-11-27

Family

ID=39661331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/063187 WO2008144253A1 (fr) 2007-05-14 2008-05-09 Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci

Country Status (1)

Country Link
WO (1) WO2008144253A1 (fr)

Cited By (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2941948A1 (fr) * 2009-02-12 2010-08-13 Nova Decision Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
WO2011090738A3 (fr) * 2009-12-29 2011-11-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
WO2012097684A1 (fr) * 2011-01-21 2012-07-26 Abbott Laboratories Inhibiteurs de kinases à base de carboxamides bicycliques
WO2012127030A1 (fr) * 2011-03-23 2012-09-27 Proteosys Ag Arylpipérazines en tant qu'agents neuroprotecteurs
WO2012143143A1 (fr) * 2011-04-21 2012-10-26 Origenis Gmbh Composés hétérocycliques en tant qu'inhibiteurs de kinases
US8338452B2 (en) 2008-02-29 2012-12-25 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
JP2013503905A (ja) * 2009-09-04 2013-02-04 バイオジェン アイデック エムエイ インコーポレイテッド Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
WO2013030802A1 (fr) * 2011-09-01 2013-03-07 Novartis Ag Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
US8394795B2 (en) 2008-02-29 2013-03-12 Array Biopharma Inc. Pyrazole [3, 4-B] pyridine Raf inhibitors
EP2567959A1 (fr) * 2011-09-12 2013-03-13 Sanofi Dérivés d'amide d'acide 6-(4-Hydroxy-phényl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs
WO2013037390A1 (fr) * 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) * 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2013060636A1 (fr) * 2011-10-25 2013-05-02 Sanofi Dérivés d'amide de l'acide 6-(4-hydroxy-phényl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinases
WO2013163109A1 (fr) * 2012-04-23 2013-10-31 Genentech, Inc. Intermédiaires et procédés de préparation de composés
WO2013167403A1 (fr) * 2012-05-09 2013-11-14 Sanofi Dérivés de 6-(4-hydroxyphényl)-1h-pyrazolo[3,4-b]pyridine substitués utilisés comme inhibiteurs de kinases
CN103443102A (zh) * 2011-01-21 2013-12-11 Abbvie公司 激酶的双环甲酰胺抑制剂
WO2014044691A1 (fr) * 2012-09-20 2014-03-27 Bayer Pharma Aktiengesellschaft Pyrrolopyrimidinylaminobenzothiazolones substituées comme inhibiteurs de mknk kinase
WO2014102377A1 (fr) * 2012-12-28 2014-07-03 Oribase Pharma Dérivés aza-indoliques utilisés comme inhibiteurs de multiples kinases
WO2014100620A3 (fr) * 2012-12-21 2014-08-21 Plexxikon Inc. Composés et procédés pour la modulation de kinase, et indications associées
WO2014132220A1 (fr) * 2013-03-01 2014-09-04 Novartis Ag Formes solides de dérivés hétérocycliques bicycliques utilisées en tant que médiateurs du récepteur pdgf
US8829195B2 (en) 2012-05-15 2014-09-09 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104098564A (zh) * 2014-07-30 2014-10-15 天津市斯芬克司药物研发有限公司 一种吡唑并吡啶化合物及其制备方法
CN104844566A (zh) * 2014-12-12 2015-08-19 中国科学院合肥物质科学研究院 一种新型结构的激酶抑制剂
CN104876879A (zh) * 2015-04-14 2015-09-02 中国科学院合肥物质科学研究院 一种新型的bcr-abl激酶抑制剂
WO2015089481A3 (fr) * 2013-12-13 2015-10-29 Dana-Farber Cancer Institute, Inc. Procédé pour traiter un lymphome lymphoplasmocytaire
US9233111B2 (en) 2011-07-08 2016-01-12 Novartis Ag Pyrrolo pyrimidine derivatives
JP2016504345A (ja) * 2012-12-28 2016-02-12 オリバーズ・ファルマ タンパク質キナーゼ阻害薬
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9278981B2 (en) 2012-05-15 2016-03-08 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
JP2016507509A (ja) * 2012-12-28 2016-03-10 オリバーズ・ファルマ タンパク質キナーゼの阻害薬としてのアザインドール誘導体
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9296757B2 (en) 2012-05-21 2016-03-29 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
US9315489B2 (en) 2012-05-15 2016-04-19 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
WO2016065226A1 (fr) * 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Composés indolecarboxamides utiles comme inhibiteurs de kinase
US9340537B2 (en) 2012-05-15 2016-05-17 Novatis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US9340557B2 (en) 2013-03-12 2016-05-17 Vertex Pharmaceuticals Incorporated Substituted quinoxaline DNA-PK inhibitors
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
CN105801584A (zh) * 2016-03-16 2016-07-27 中国药科大学 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途
US9447106B2 (en) 2013-04-25 2016-09-20 Beigene, Ltd. Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
US9505784B2 (en) 2009-06-12 2016-11-29 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9856223B2 (en) 2013-12-13 2018-01-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JP2018502899A (ja) * 2015-01-20 2018-02-01 无▲錫▼福祈制▲薬▼有限公司Ｗｕｘｉ Ｆｏｒｔｕｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ Ｊａｋ阻害剤
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2018053437A1 (fr) 2016-09-19 2018-03-22 Mei Pharma, Inc. Polythérapie
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US10039761B2 (en) 2013-10-17 2018-08-07 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10112957B2 (en) 2014-10-22 2018-10-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US10618887B2 (en) 2012-06-08 2020-04-14 Sunesis Pharmaceuticals, Inc. Pyrimidinyl tyrosine kinase inhibitors
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2020156271A1 (fr) * 2019-02-02 2020-08-06 江苏威凯尔医药科技有限公司 Inhibiteur de la famille des janus kinases (jak), sa préparation et ses applications
CN111518096A (zh) * 2019-02-02 2020-08-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10906889B2 (en) 2013-10-18 2021-02-02 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US10927117B2 (en) 2016-08-16 2021-02-23 Beigene Switzerland Gmbh Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11040957B2 (en) 2013-10-18 2021-06-22 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US11174243B2 (en) 2016-07-21 2021-11-16 Sunesis Pharmaceuticals, Inc. Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11186637B2 (en) 2013-09-13 2021-11-30 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11512132B2 (en) 2014-07-03 2022-11-29 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
US11534431B2 (en) 2016-07-05 2022-12-27 Beigene Switzerland Gmbh Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
WO2023208174A1 (fr) * 2022-04-28 2023-11-02 杭州普济远成生物医药科技有限公司 Inhibiteur de désubiquitinase et son utilisation
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007017143A1 (fr) * 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Derives de l'azabenzimidazole, leur fabrication et leur utilisation en tant qu'agents anticancereux
WO2007042321A2 (fr) * 2005-10-13 2007-04-19 Devgen N.V. Inhibiteur de kinase
WO2007083978A1 (fr) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Dérivés d'imidazopyridine inhibant l'activité de la protéine kinase, méthode de préparation de ces derniers et composition pharmaceutique les comprenant
WO2008028617A1 (fr) * 2006-09-06 2008-03-13 F. Hoffmann-La Roche Ag Dérivés hétéroaryles utilisés en tant qu'inhibiteurs de protéine kinase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007017143A1 (fr) * 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Derives de l'azabenzimidazole, leur fabrication et leur utilisation en tant qu'agents anticancereux
WO2007042321A2 (fr) * 2005-10-13 2007-04-19 Devgen N.V. Inhibiteur de kinase
WO2007083978A1 (fr) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Dérivés d'imidazopyridine inhibant l'activité de la protéine kinase, méthode de préparation de ces derniers et composition pharmaceutique les comprenant
WO2008028617A1 (fr) * 2006-09-06 2008-03-13 F. Hoffmann-La Roche Ag Dérivés hétéroaryles utilisés en tant qu'inhibiteurs de protéine kinase

Cited By (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338452B2 (en) 2008-02-29 2012-12-25 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
US8394795B2 (en) 2008-02-29 2013-03-12 Array Biopharma Inc. Pyrazole [3, 4-B] pyridine Raf inhibitors
WO2010092489A1 (fr) * 2009-02-12 2010-08-19 Nova Decision Dérivés d'azaindoles comme inhibiteurs des protéines kinases abl et src
US8580815B2 (en) 2009-02-12 2013-11-12 Oribase Pharma Derivatives of azaindoles as inhibitors of protein kinases ABL and SRC
JP2012517465A (ja) * 2009-02-12 2012-08-02 オリバーズ・ファルマ プロテインキナーゼａｂｌおよびｓｒｃの阻害剤としてのアザインドール誘導体
FR2941948A1 (fr) * 2009-02-12 2010-08-13 Nova Decision Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
US9505784B2 (en) 2009-06-12 2016-11-29 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US10577374B2 (en) 2009-09-04 2020-03-03 Sunesis Pharmaceuticals, Inc. Bruton's tyrosine kinase inhibitors
JP2013503905A (ja) * 2009-09-04 2013-02-04 バイオジェン アイデック エムエイ インコーポレイテッド Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
US9249146B2 (en) 2009-09-04 2016-02-02 Biogen Ma Inc. Bruton'S tyrosine kinase inhibitors
JP2018111726A (ja) * 2009-09-04 2018-07-19 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
US9790229B2 (en) 2009-09-04 2017-10-17 Sunesis Pharmaceuticals, Inc. Bruton's tyrosine kinase inhibitors
JP2017186373A (ja) * 2009-09-04 2017-10-12 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
EP2937345A3 (fr) * 2009-12-29 2015-12-02 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase raf de type ii
US20160046636A1 (en) * 2009-12-29 2016-02-18 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
US11826365B2 (en) 2009-12-29 2023-11-28 Dana-Farber Cancer Institute, Inc. Type II raf kinase inhibitors
WO2011090738A3 (fr) * 2009-12-29 2011-11-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
AU2016201096B2 (en) * 2009-12-29 2017-08-31 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
US20130040949A1 (en) * 2009-12-29 2013-02-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
US9358231B2 (en) 2009-12-29 2016-06-07 Dana-Farber Cancer Institute, Inc. Type II RAF kinase inhibitors
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10213427B2 (en) 2010-12-22 2019-02-26 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10813930B2 (en) 2010-12-22 2020-10-27 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN103443102A (zh) * 2011-01-21 2013-12-11 Abbvie公司 激酶的双环甲酰胺抑制剂
WO2012097684A1 (fr) * 2011-01-21 2012-07-26 Abbott Laboratories Inhibiteurs de kinases à base de carboxamides bicycliques
WO2012127030A1 (fr) * 2011-03-23 2012-09-27 Proteosys Ag Arylpipérazines en tant qu'agents neuroprotecteurs
US9499535B2 (en) 2011-04-21 2016-11-22 Origenis Gmbh Kinase inhibitors
CN103717597A (zh) * 2011-04-21 2014-04-09 原真股份有限公司 作为激酶抑制剂的杂环化合物
JP2014511884A (ja) * 2011-04-21 2014-05-19 オリゲニス ゲーエムベーハー キナーゼ・インヒビターとしての複素環化合物
WO2012143143A1 (fr) * 2011-04-21 2012-10-26 Origenis Gmbh Composés hétérocycliques en tant qu'inhibiteurs de kinases
EA034193B1 (ru) * 2011-04-21 2020-01-15 Оригенис Гмбх Гетероциклические соединения в качестве ингибиторов киназ
US9233111B2 (en) 2011-07-08 2016-01-12 Novartis Ag Pyrrolo pyrimidine derivatives
JP2014527544A (ja) * 2011-09-01 2014-10-16 ノバルティス アーゲー 肺動脈性高血圧の処置のための二環式ヘテロ環誘導体
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CN104024252A (zh) * 2011-09-01 2014-09-03 诺华股份有限公司 用于治疗肺动脉高压的双环杂环衍生物
EA024068B1 (ru) * 2011-09-01 2016-08-31 Новартис Аг Производные бициклических гетероциклов для лечения пульмонарной артериальной гипертонии
KR101687082B1 (ko) 2011-09-01 2016-12-15 노파르티스 아게 폐동맥 고혈압의 치료를 위한 비시클릭 헤테로사이클 유도체
US9751876B2 (en) 2011-09-01 2017-09-05 Novartis Ag Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CN105001218B (zh) * 2011-09-01 2017-04-12 诺华股份有限公司 用于治疗肺动脉高压的双环杂环衍生物
CN104024252B (zh) * 2011-09-01 2015-08-26 诺华股份有限公司 用于治疗肺动脉高压的双环杂环衍生物
WO2013030802A1 (fr) * 2011-09-01 2013-03-07 Novartis Ag Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
AU2012303674B2 (en) * 2011-09-01 2015-11-26 Novartis Ag Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
KR20140059272A (ko) * 2011-09-01 2014-05-15 노파르티스 아게 폐동맥 고혈압의 치료를 위한 비시클릭 헤테로사이클 유도체
CN105001218A (zh) * 2011-09-01 2015-10-28 诺华股份有限公司 用于治疗肺动脉高压的双环杂环衍生物
EP2567959A1 (fr) * 2011-09-12 2013-03-13 Sanofi Dérivés d'amide d'acide 6-(4-Hydroxy-phényl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs
WO2013037390A1 (fr) * 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (fr) * 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
US8686150B2 (en) 2011-09-27 2014-04-01 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013060636A1 (fr) * 2011-10-25 2013-05-02 Sanofi Dérivés d'amide de l'acide 6-(4-hydroxy-phényl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinases
US10144730B2 (en) 2011-11-17 2018-12-04 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US10981903B2 (en) 2011-11-17 2021-04-20 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
KR20150005995A (ko) * 2012-04-23 2015-01-15 제넨테크, 인크. 화합물의 제조를 위한 중간체 및 방법
US9221813B2 (en) 2012-04-23 2015-12-29 Genentech, Inc. Intermediates and processes for preparing compounds
CN104395311B (zh) * 2012-04-23 2017-04-19 基因泰克公司 制备化合物的中间体和方法
JP2015514784A (ja) * 2012-04-23 2015-05-21 ジェネンテック， インコーポレイテッド 化合物の調製のための中間体及び方法
KR102096679B1 (ko) 2012-04-23 2020-04-02 제넨테크, 인크. 화합물의 제조를 위한 중간체 및 방법
CN104395311A (zh) * 2012-04-23 2015-03-04 基因泰克公司 制备化合物的中间体和方法
WO2013163109A1 (fr) * 2012-04-23 2013-10-31 Genentech, Inc. Intermédiaires et procédés de préparation de composés
US11021465B2 (en) 2012-04-24 2021-06-01 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10501439B2 (en) 2012-04-24 2019-12-10 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US11008305B2 (en) 2012-04-24 2021-05-18 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10442791B2 (en) 2012-04-24 2019-10-15 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9878993B2 (en) 2012-04-24 2018-01-30 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors for treatment of cancer
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10076521B2 (en) 2012-04-24 2018-09-18 Vertex Pharamceuticals Incorporated DNA-PK inhibitors
US9376448B2 (en) 2012-04-24 2016-06-28 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9592232B2 (en) 2012-04-24 2017-03-14 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10391095B2 (en) 2012-04-24 2019-08-27 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9925188B2 (en) 2012-04-24 2018-03-27 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors and uses thereof
WO2013167403A1 (fr) * 2012-05-09 2013-11-14 Sanofi Dérivés de 6-(4-hydroxyphényl)-1h-pyrazolo[3,4-b]pyridine substitués utilisés comme inhibiteurs de kinases
US9133181B2 (en) 2012-05-09 2015-09-15 Sanofi Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
US9315489B2 (en) 2012-05-15 2016-04-19 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US9458112B2 (en) 2012-05-15 2016-10-04 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US9896444B2 (en) 2012-05-15 2018-02-20 Novartis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US9278981B2 (en) 2012-05-15 2016-03-08 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US9340537B2 (en) 2012-05-15 2016-05-17 Novatis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US8829195B2 (en) 2012-05-15 2014-09-09 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US9296757B2 (en) 2012-05-21 2016-03-29 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
US10618887B2 (en) 2012-06-08 2020-04-14 Sunesis Pharmaceuticals, Inc. Pyrimidinyl tyrosine kinase inhibitors
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11840534B2 (en) 2012-06-13 2023-12-12 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US10131667B2 (en) 2012-06-13 2018-11-20 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9745311B2 (en) 2012-08-10 2017-08-29 Incyte Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
JP2015529232A (ja) * 2012-09-20 2015-10-05 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピロロピリミジニルアミノ−ベンゾチアゾロン
WO2014044691A1 (fr) * 2012-09-20 2014-03-27 Bayer Pharma Aktiengesellschaft Pyrrolopyrimidinylaminobenzothiazolones substituées comme inhibiteurs de mknk kinase
US9382255B2 (en) 2012-09-20 2016-07-05 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors
US10787436B2 (en) 2012-10-18 2020-09-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10752624B2 (en) 2012-10-19 2020-08-25 Origenis Gmbh Kinase inhibitors
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN105308036A (zh) * 2012-12-21 2016-02-03 普莱希科公司 用于激酶调节的化合物和方法及其适应症
US9676748B2 (en) 2012-12-21 2017-06-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP2016509583A (ja) * 2012-12-21 2016-03-31 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節のための化合物および方法、ならびにその適応
US10301280B2 (en) 2012-12-21 2019-05-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2014100620A3 (fr) * 2012-12-21 2014-08-21 Plexxikon Inc. Composés et procédés pour la modulation de kinase, et indications associées
CN105308036B (zh) * 2012-12-21 2019-06-21 普莱希科公司 用于激酶调节的化合物和方法及其适应症
TWI617552B (zh) * 2012-12-21 2018-03-11 普雷辛肯公司 用於激酶調節及其適應症之化合物及方法
US9403823B2 (en) 2012-12-28 2016-08-02 Oribase Pharma Protein kinase inhibitors
JP2016504345A (ja) * 2012-12-28 2016-02-12 オリバーズ・ファルマ タンパク質キナーゼ阻害薬
US9493455B2 (en) 2012-12-28 2016-11-15 Oribase Pharma Azaindole derivatives as inhibitors of protein kinases
US9550772B2 (en) 2012-12-28 2017-01-24 Oribase Pharma Azaindole derivatives as multi kinase inhibitors
FR3000492A1 (fr) * 2012-12-28 2014-07-04 Oribase Pharma Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
JP2016507509A (ja) * 2012-12-28 2016-03-10 オリバーズ・ファルマ タンパク質キナーゼの阻害薬としてのアザインドール誘導体
WO2014102377A1 (fr) * 2012-12-28 2014-07-03 Oribase Pharma Dérivés aza-indoliques utilisés comme inhibiteurs de multiples kinases
JP2016507508A (ja) * 2012-12-28 2016-03-10 オリバーズ・ファルマ マルチキナーゼ阻害薬としてのアザインドール誘導体
WO2014132220A1 (fr) * 2013-03-01 2014-09-04 Novartis Ag Formes solides de dérivés hétérocycliques bicycliques utilisées en tant que médiateurs du récepteur pdgf
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US10786512B2 (en) 2013-03-12 2020-09-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9987284B2 (en) 2013-03-12 2018-06-05 Vertex Pharmaceuticals Incorporated Substituted benzooxadiazole DNA-PK inhibitors
US9340557B2 (en) 2013-03-12 2016-05-17 Vertex Pharmaceuticals Incorporated Substituted quinoxaline DNA-PK inhibitors
US9359380B2 (en) 2013-03-12 2016-06-07 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10973830B2 (en) 2013-03-12 2021-04-13 Vertex Pharmaceuticals Incorporated Substituted quinoxaline DNA-PK inhibitors
US11813267B2 (en) 2013-03-12 2023-11-14 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10258627B2 (en) 2013-03-12 2019-04-16 Vertex Pharmaceutical Incorporated DNA-PK inhibitors
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10040790B2 (en) 2013-04-19 2018-08-07 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10450313B2 (en) 2013-04-19 2019-10-22 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10947230B2 (en) 2013-04-19 2021-03-16 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11530214B2 (en) 2013-04-19 2022-12-20 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9556188B2 (en) 2013-04-25 2017-01-31 Beigene, Ltd. Substituted imidazo[1,2-b]pyrazoles as bruton'S tyrosine kinase modulators
US10005782B2 (en) 2013-04-25 2018-06-26 Beigene, Ltd. Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
US9447106B2 (en) 2013-04-25 2016-09-20 Beigene, Ltd. Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
US10570139B2 (en) 2013-04-25 2020-02-25 Beigene Switzerland Gmbh Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
US11142528B2 (en) 2013-04-25 2021-10-12 Beigene Switzerland Gmbh Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
US11186637B2 (en) 2013-09-13 2021-11-30 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
US11673951B2 (en) 2013-09-13 2023-06-13 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
US10716789B2 (en) 2013-10-17 2020-07-21 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US10039761B2 (en) 2013-10-17 2018-08-07 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US10906889B2 (en) 2013-10-18 2021-02-02 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US11040957B2 (en) 2013-10-18 2021-06-22 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US10633348B2 (en) 2013-12-13 2020-04-28 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2015089481A3 (fr) * 2013-12-13 2015-10-29 Dana-Farber Cancer Institute, Inc. Procédé pour traiter un lymphome lymphoplasmocytaire
US9908872B2 (en) 2013-12-13 2018-03-06 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US10597387B2 (en) 2013-12-13 2020-03-24 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US9856223B2 (en) 2013-12-13 2018-01-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US11512132B2 (en) 2014-07-03 2022-11-29 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
CN104098564A (zh) * 2014-07-30 2014-10-15 天津市斯芬克司药物研发有限公司 一种吡唑并吡啶化合物及其制备方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10464949B2 (en) 2014-10-22 2019-11-05 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
US10844077B2 (en) 2014-10-22 2020-11-24 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
US10112957B2 (en) 2014-10-22 2018-10-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
WO2016065226A1 (fr) * 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Composés indolecarboxamides utiles comme inhibiteurs de kinase
EA034931B1 (ru) * 2014-10-24 2020-04-08 Бристол-Майерс Сквибб Компани Индолкарбоксамидные соединения
US10604504B2 (en) 2014-10-24 2020-03-31 Bristol-Myers Squibb Company Indole carboxamide compounds
US9688629B2 (en) 2014-10-24 2017-06-27 Bristol-Myers Squibb Company Indole carboxamide compounds
EA032277B1 (ru) * 2014-10-24 2019-05-31 Бристол-Майерс Сквибб Компани Индолкарбоксамидные соединения
CN107108583A (zh) * 2014-10-24 2017-08-29 百时美施贵宝公司 可用作激酶抑制剂的吲哚甲酰胺化合物
US10329274B2 (en) 2014-10-24 2019-06-25 Bristol-Myers Squibb Company Indole carboxamide compounds
US11623921B2 (en) 2014-10-24 2023-04-11 Bristol-Myers Squibb Company Indole carboxamide compounds
US9802915B2 (en) 2014-10-24 2017-10-31 Bristol-Myers Squibb Company Indole carboxamide compounds
US9920031B2 (en) 2014-10-24 2018-03-20 Bristol-Myers Squibb Company Indole carboxamide compounds
EP3461821A1 (fr) * 2014-10-24 2019-04-03 Bristol-Myers Squibb Company Dérivés d'indole carboxamide en tant qu'inhibiteurs de kinase
CN107108583B (zh) * 2014-10-24 2020-11-13 百时美施贵宝公司 可用作激酶抑制剂的吲哚甲酰胺化合物
AU2019283921B2 (en) * 2014-10-24 2021-01-07 Bristol-Myers Squibb Company Indole carboxamide compounds useful as kinase inhibitors
CN104844566A (zh) * 2014-12-12 2015-08-19 中国科学院合肥物质科学研究院 一种新型结构的激酶抑制剂
CN104844566B (zh) * 2014-12-12 2018-05-18 合肥中科普瑞昇生物医药科技有限公司 一种新型结构的激酶抑制剂
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP2018502899A (ja) * 2015-01-20 2018-02-01 无▲錫▼福祈制▲薬▼有限公司Ｗｕｘｉ Ｆｏｒｔｕｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ Ｊａｋ阻害剤
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10738048B2 (en) 2015-02-20 2020-08-11 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9801889B2 (en) 2015-02-20 2017-10-31 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10251892B2 (en) 2015-02-20 2019-04-09 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10016438B2 (en) 2015-02-20 2018-07-10 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10214528B2 (en) 2015-02-20 2019-02-26 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11014923B2 (en) 2015-02-20 2021-05-25 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11667635B2 (en) 2015-02-20 2023-06-06 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10632126B2 (en) 2015-02-20 2020-04-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US11325910B2 (en) 2015-03-27 2022-05-10 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016165205A1 (fr) * 2015-04-14 2016-10-20 中国科学院合肥物质科学研究院 Nouvel inhibiteur de kinase bcr-abl
CN104876879A (zh) * 2015-04-14 2015-09-02 中国科学院合肥物质科学研究院 一种新型的bcr-abl激酶抑制剂
CN104876879B (zh) * 2015-04-14 2018-05-18 中国科学院合肥物质科学研究院 一种bcr-abl激酶抑制剂
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN105801584A (zh) * 2016-03-16 2016-07-27 中国药科大学 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途
US11534431B2 (en) 2016-07-05 2022-12-27 Beigene Switzerland Gmbh Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
US11174243B2 (en) 2016-07-21 2021-11-16 Sunesis Pharmaceuticals, Inc. Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
US11591340B2 (en) 2016-08-16 2023-02-28 Beigene Switzerland Gmbh Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11884674B2 (en) 2016-08-16 2024-01-30 Beigene Switzerland Gmbh Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11851437B2 (en) 2016-08-16 2023-12-26 Beigene Switzerland Gmbh Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US10927117B2 (en) 2016-08-16 2021-02-23 Beigene Switzerland Gmbh Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11814389B2 (en) 2016-08-16 2023-11-14 Beigene Switzerland Gmbh Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
WO2018053437A1 (fr) 2016-09-19 2018-03-22 Mei Pharma, Inc. Polythérapie
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
CN111518096A (zh) * 2019-02-02 2020-08-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
JP2022518556A (ja) * 2019-02-02 2022-03-15 江蘇威凱爾医薬科技有限公司 ヤーヌスキナーゼ（ｊａｋ）ファミリー阻害剤及びその調製と使用
WO2020156271A1 (fr) * 2019-02-02 2020-08-06 江苏威凯尔医药科技有限公司 Inhibiteur de la famille des janus kinases (jak), sa préparation et ses applications
CN111518096B (zh) * 2019-02-02 2022-02-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
JP7344304B2 (ja) 2019-02-02 2023-09-13 江蘇威凱爾医薬科技有限公司 ヤーヌスキナーゼ（ｊａｋ）ファミリー阻害剤及びその調製と使用
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2023208174A1 (fr) * 2022-04-28 2023-11-02 杭州普济远成生物医药科技有限公司 Inhibiteur de désubiquitinase et son utilisation
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
US11896596B2 (en) 2022-06-08 2024-02-13 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
US11911386B2 (en) 2022-06-08 2024-02-27 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Similar Documents

Publication Publication Date Title
WO2008144253A1 (fr) Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci
AU2008265843B2 (en) Protein kinase inhibitors and methods for using thereof
KR101079520B1 (ko) Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 수용체를 조절하기 위한 조성물 및 방법
WO2008112695A2 (fr) Inhibiteurs de protéine kinase et procédés d'utilisation de ceux-ci
AU2008289135B2 (en) 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
WO2008124393A1 (fr) Derives de benzothiazole et leur utilisation en tant qu'inhibiteurs des proteines kinases
US20100184765A1 (en) Protein Kinase Inhibitors and Methods for Using Thereof
ES2477878T3 (es) Compuestos y composiciones de 5-(4-(aloalcoxi)fenil)pirimidin-2-amina como inhibidores de quinasas
US20080300246A1 (en) Compounds and Compositions as Protein Kinase Inhibitors
WO2006124731A2 (fr) Composes et compositions utilise(e)s en tant qu'inhibiteurs de proteines-kinases
KR20090029832A (ko) 단백질 키나제 억제제로서의 [4,5']비피리미디닐-6,4'-디아민 유도체
CA2664147A1 (fr) Inhibiteurs de la proteine kinase et procedes pour utiliser ceux-ci
MXPA06015147A (es) Compuestos y composiciones como inhibidores de la proteincinasa.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08769378

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08769378

Country of ref document: EP

Kind code of ref document: A1